The Results of Intravitreal Bevacizumab Monotherapy for Treating Aggressive Posterior Retinopathy of Prematurity and Type 1 Retinopathy of Prematurity

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2021 Jan 30

PMID 33514904

Citations 4

Authors

Aysegul Comez

Yalcin Karakucuk

Mehmet Cuneyt Ozmen

Pelin Celemler

Oguzhan Saygili

Affiliations

Soon will be listed here.

Abstract

Objectives: This study evaluated the efficacy of intravitreal bevacizumab (IVB) monotherapy for aggressive posterior retinopathy of prematurity (APROP) and Type 1 retinopathy of prematurity (ROP), along with recurrence rates and treatment outcomes for recurrences.

Methods: This retrospective cohort study reviewed the records of infants with ROP (Type 1 and APROP), who received IVB treatment between March 2013 and February 2018.

Results: A total of 257 eyes from 130 cases (unilateral eyes in three cases) were included. Cases were followed for 121.7 ± 45.7 weeks (range: 70-260 weeks). Recurrence requiring treatment was determined in 14.8% of all eyes at a mean of 9.6 ± 2.7 weeks (range: 6-15 weeks) after initial treatment and a mean of 42.3 ± 2.2 weeks (range: 38-48 weeks) postmenstrual age. Recurrence requiring treatment was observed in 20.8% of APROP and 5.8% of Type 1 ROP eyes at a statistically significant difference (p = 0.001). Persistent avascular areas were found in 54 eyes (25.8%) at the corrected age of 1 year, and prophylactic laser treatment was applied. This was statistically significantly higher in APROP (38.6%) than in Type 1 ROP (10.5%) (p < 0.001). An unfavourable structural outcome (progression to retinal detachment) occurred in one eye (0.4%), which developed insufficient regression and progression.

Conclusions: IVB monotherapy is effective for APROP and Type 1 ROP with Zone 1 and posterior Zone 2 localisation. However, because of recurrences requiring treatment and persistent peripheral avascular areas, severe, late complications must be considered, and follow-up examinations must be made. Prophylactic laser treatment for persistent avascular areas seems effective for minimising long-term complications.

Citing Articles

Research hotspots and trends in retinopathy of prematurity from 2003 to 2022: a bibliometric analysis.

Zhang Y, Chai X, Fan Z, Zhang S, Zhang G Front Pediatr. 2023; 11:1273413.

PMID: 37854031 PMC: 10579817. DOI: 10.3389/fped.2023.1273413.

Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity.

Bhat V, Patil S Oman J Ophthalmol. 2023; 16(2):233-236.

PMID: 37602171 PMC: 10433051. DOI: 10.4103/ojo.ojo_120_22.

Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity.

Jang J, Kang Y, Park H, Kim K, Kim S, Han J BMJ Open Ophthalmol. 2023; 8(1).

PMID: 37278416 PMC: 9884904. DOI: 10.1136/bmjophth-2022-001166.

Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

Freedman S, Hercinovic A, Wallace D, Kraker R, Li Z, Bhatt A Ophthalmology. 2022; 129(10):1120-1128.

PMID: 35660415 PMC: 9509410. DOI: 10.1016/j.ophtha.2022.05.019.

References

Sapieha P, Joyal J, Rivera J, Kermorvant-Duchemin E, Sennlaub F, Hardy P . Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest. 2010; 120(9):3022-32. PMC: 2929716. DOI: 10.1172/JCI42142. View

Cavallaro G, Filippi L, Bagnoli P, la Marca G, Cristofori G, Raffaeli G . The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol. 2013; 92(1):2-20. DOI: 10.1111/aos.12049. View

Good W . Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2005; 102:233-48. PMC: 1280104. View

Geloneck M, Chuang A, Clark W, Hunt M, Norman A, Packwood E . Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014; 132(11):1327-33. DOI: 10.1001/jamaophthalmol.2014.2772. View

Mintz-Hittner H, Kennedy K, Chuang A . Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7):603-15. PMC: 3119530. DOI: 10.1056/NEJMoa1007374. View

Chen J, Smith L . Retinopathy of prematurity. Angiogenesis. 2007; 10(2):133-40. DOI: 10.1007/s10456-007-9066-0. View

Sankar M, Sankar J, Mehta M, Bhat V, Srinivasan R . Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2016; 2:CD009734. DOI: 10.1002/14651858.CD009734.pub2. View

Pertl L, Steinwender G, Mayer C, Hausberger S, Poschl E, Wackernagel W . A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. PLoS One. 2015; 10(6):e0129383. PMC: 4470662. DOI: 10.1371/journal.pone.0129383. View

Mintz-Hittner H . Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes. J AAPOS. 2016; 20(6):478-480. DOI: 10.1016/j.jaapos.2016.10.002. View

10.

Palmer E . Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP). Doc Ophthalmol. 1990; 74(3):245-51. DOI: 10.1007/BF02482615. View

11.

Ittiara S, Blair M, Shapiro M, Lichtenstein S . Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013; 17(3):323-5. DOI: 10.1016/j.jaapos.2013.01.004. View

12.

Patel R, Blair M, Shapiro M, Lichtenstein S . Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012; 130(6):801-2. DOI: 10.1001/archophthalmol.2011.1802. View

13.

Hu J, Blair M, Shapiro M, Lichtenstein S, Galasso J, Kapur R . Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012; 130(8):1000-6. DOI: 10.1001/archophthalmol.2012.592. View

14.

Sanghi G, Dogra M, Das P, Vinekar A, Gupta A, Dutta S . Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina. 2009; 29(9):1335-9. DOI: 10.1097/IAE.0b013e3181a68f3a. View

15.

Yetik H, Gunay M, Sirop S, Salihoglu Z . Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol. 2014; 253(10):1677-83. DOI: 10.1007/s00417-014-2867-0. View

16.

Garcia Gonzalez J, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M . PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY. Retina. 2017; 38(4):764-772. DOI: 10.1097/IAE.0000000000001581. View

17.

Martinez-Castellanos M, Gonzalez-H Leon A, Romo-Aguas J, Gonzalez-Gonzalez L . A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series. Graefes Arch Clin Exp Ophthalmol. 2020; 258(4):767-772. DOI: 10.1007/s00417-020-04605-y. View

18.

Hwang C, Hubbard G, Hutchinson A, Lambert S . Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Ophthalmology. 2015; 122(5):1008-15. PMC: 4414677. DOI: 10.1016/j.ophtha.2014.12.017. View

19.

Ling K, Liao P, Wang N, Chao A, Chen K, Chen T . RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY. Retina. 2019; 40(9):1793-1803. DOI: 10.1097/IAE.0000000000002663. View

20.

Mintz-Hittner H, Geloneck M, Chuang A . Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. Ophthalmology. 2016; 123(9):1845-55. PMC: 4995132. DOI: 10.1016/j.ophtha.2016.04.028. View